XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Cervical Cancer Channel
subscribe to Cervical Cancer newsletter

Latest Research : Cancer : Cervical Cancer

   DISCUSS   |   EMAIL   |   PRINT
Clues to 'disappearing' precancers uncovered
Jul 1, 2005, 12:57, Reviewed by: Dr.

Trimble was particularly interested in these molecular differences because she is using HPV-targeted vaccines in related studies to treat early cervical lesions before they turn into cancer. "It's important for us to know the immunologic fingerprint of women who may best benefit from our vaccine," she says. "Some lesions are on the brink of resolving, but may need the vaccine to push them over."

 
New research sheds light on why cervical precancers disappear in some women and not in others. Scientists at the Johns Hopkins Kimmel Cancer Center report in the July 1 issue of Clinical Cancer Research that the reason many of these lesions persist is an unlikely mix of human papilloma virus (HPV) strain and a woman's individual immune system.

For decades, scientists have known that HPV causes nearly all cases of cancer in the neck of the womb. Most sexually active women some reports say up to 80 percent are exposed to HPV and more than half of these women are infected with strains of the virus that could likely turn a precancerous lesion to cancer. But only a small percentage of precancers progress to full-blown cancer, a process that takes years.

To find out why, gynecologic oncologist Cornelia Trimble, M.D., closely monitored 100 women with high-grade, precancerous cervical lesions before standard surgery to remove the abnormal tissue. Some of the lesions about 28 percent -- regressed by themselves before surgery within a time period considered within the bounds of care standards. But among patients whose pre-cancers lingered, Trimble discovered that women were three times less likely to resolve their lesions if they carried a certain immune system gene and did not have HPV16, the most common strain of the virus.

Trimble was particularly interested in these molecular differences because she is using HPV-targeted vaccines in related studies to treat early cervical lesions before they turn into cancer. "It's important for us to know the immunologic fingerprint of women who may best benefit from our vaccine," she says. "Some lesions are on the brink of resolving, but may need the vaccine to push them over."

Lesions containing HPV16 alone are the most troublesome and difficult to resolve. In the subset of 44 patients with HPV16 only, their type of immune system made no impact on whether or not their lesion resolved. But in 30 women with non-HPV16 lesions, those who carry a gene called HLA*A201 were three times less likely to clear up their lesions than those without the gene (14.3 percent vs. 42.3 percent). According to Trimble, 40 percent of people carry the HLA*A201 gene, which codes for certain white blood cell proteins.

None of the lesions got worse during the study period, and all unresolved lesions were surgically removed when the observation period ended. "Since none of the lesions progressed after 15 weeks, we can be reasonably assured that this window of time is safe for vaccine treatments," she said.

Trimble is studying a larger group of patients to confirm her results and rule out other potentially confounding factors such as age, smoking status, and contraceptive method, which may influence how these lesions clear. Trimble recently published results linking second-hand cigarette smoke to cervical cancer progression. She also is looking for additional immune system characteristics that could predict mechanisms of immune responses to HPV. This may provide more information on which women have lesions more likely to regress and potentially avoid surgery, plus provide the opportunity to treat early-stage disease.
 

- July 1 issue of Clinical Cancer Research
 

http://www.hopkinsmedicine.org/cervicaldysplasia

 
Subscribe to Cervical Cancer Newsletter
E-mail Address:

 

According to the Centers for Disease Control, an estimated 20 million people in the United States are infected with HPV and up to three-quarters of these have viral strains that are linked to cervical, oral and anal cancers. More than 10,000 cases of cervical cancer are diagnosed in the United States annually.

The research was funded by the National Cancer Institute and Cigarette Restitution Fund Program.

Trimble's research collaborators include Steven Piantadosi, Patti Gravitt, Brigitte Ronnett, Ellen Pizer, Andrea Elko, Barbara Wilgus, William Yutzy, Richard Daniel, Keerti Shah, Shiwen Peng, Chienfu Hung, Richard Roden, T.C. Wu, and Drew Pardoll.


Related Cervical Cancer News

New vaccine prevents cervical cancer in teens
Topotecan for Late-Stage Cervical Cancer Approved
New HPV vaccine is 100 percent effective
Vaccine for Cervical Cancer Approved in US - Overview
Quadrivalent Human Papillomavirus (HPV) Recombinant Vaccine Approved by FDA
HPV Vaccination: Predicting Its Effect on Cervical Cancer Rates
HPV testing is more sensitive for screening cervical cancer
Community's income status predicts cervical screening rates
Novel technique to remove "inoperable" cervical spinal tumours
HPV Vaccine Prevented 100 Percent of Cervical Pre-cancers


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us